HIGHLIGHTS
- who: Zalypsis et al. from the (UNIVERSITY) have published the paper: Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis, in the Journal: (JOURNAL)
- what: The aim of this study was to identify biomarkers defining the molecular basis of sensitivity/resistance to Zalypsis to assist in its clinical development. The authors propose the use of a specific tyrosine kinase inhibitor according to the RTK active in the patient's tumor, thus promoting personalized treatment.
SUMMARY
Treatment of cells lines with Zalypsis leads to cell cycle delay in S . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.